Date:\_\_\_\_\_June 12,2022\_\_\_

Your Name:\_\_\_\_\_Jennifer Velloza\_\_

Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u>

Manuscript number (if known): thelancethiv-D-21-00494

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   | Funding for research to my institution  |
|   | manuscript (e.g., funding, provision of study materials, | NIH  |   |
|   | medical writing, article                                 |  |   |
|   | processing charges, etc.)                                |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | XNone  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | XNone  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | XNone  |   |
|   |  |  |   |
|   |  |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert<br>testimony | XNone  |
|----|---|--------|
| 7  | Support for attending meetings and/or travel  | XNone  |
| 8  | Patents planned, issued or<br>pending   | XNone  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board   | X_None |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid  | X_None |
| 11 | Stock or stock options  | X_None |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services   | XNone  |
| 13 | Other financial or non-<br>financial interests  | X_None |

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_\_\_\_\_5/18/2022\_

Your Name: \_\_\_\_ Deborah Donnell\_\_\_\_

Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u>

Manuscript number (if known): thelancethiv-D-21-00494

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding,    | None   |   |
|   | provision of study materials,<br>medical writing, article | NIH  | Payment to insitution   |
|   | processing charges, etc.)<br>No time limit for this item. |  |   |
|   |   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                  | xNone  |   |
|   | any entity (if not indicated<br>in item #1 above).        |  |   |
| 3 | Royalties or licenses                                     | xNone  |   |
|   |   |  |   |
|   |   |  |   |
| 4 | Consulting fees   | xNone  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | x_None |
|----|--|--------|
| 6  | Payment for expert testimony   | xNone  |
| 7  | Support for attending meetings and/or travel   | x_None |
| 8  | Patents planned, issued or pending   | _xNone |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | _xNone |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | x_None |
| 11 | Stock or stock options   | _xNone |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | x_None |
| 13 | Other financial or non-<br>financial interests   | x_None |

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 05/12/2022 Your Name: Sybil Hosek Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u> Manuscript number (if known): <u>thelancethiv-D-21-00494</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
|   |  | needed)   |   |
|   |  | Time frame: Since the initial   | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | National Institute of<br>Health (NIH) funding   | To institution  |
|   | medical writing, article   |   |   |
|   | processing charges, etc.)  |   |   |
|   | No time limit for this item.   |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  | Time frame: past  | 26 months   |
| 2 | Grants or contracts from   | NIH   | Somontins   |
| - | any entity (if not indicated   |   |   |
|   | in item #1 above).   |   |   |
| 3 | Royalties or licenses  | None  |   |
|   |  |   |   |
|   |  |   |   |
| 4 | Consulting fees  | None  |   |

|    |                              |      | 1 |
|----|------------------------------|------|---|
|    |                              |      |   |
|    |                              |      |   |
| 5  | Payment or honoraria for     | None |   |
|    | lectures, presentations,     |      |   |
|    | speakers bureaus,            |      |   |
|    | manuscript writing or        |      |   |
|    | educational events           |      |   |
| 6  | Payment for expert           | None |   |
|    | testimony                    |      |   |
|    |                              |      |   |
| 7  | Support for attending        | None |   |
|    | meetings and/or travel       |      |   |
|    | meetings and/or traver       |      |   |
|    |                              |      |   |
|    |                              |      |   |
|    |                              |      |   |
| 8  | Patents planned, issued or   | None |   |
|    | pending                      |      |   |
|    |                              |      |   |
| 9  | Participation on a Data      | None |   |
|    | Safety Monitoring Board or   |      |   |
|    | Advisory Board               |      |   |
| 10 | Leadership or fiduciary role | None |   |
|    | in other board, society,     |      |   |
|    | committee or advocacy        |      |   |
|    | group, paid or unpaid        |      |   |
| 11 | Stock or stock options       | None |   |
|    |                              | None |   |
|    |                              |      |   |
| 12 | Receipt of equipment,        | None |   |
| 12 | materials, drugs, medical    |      |   |
|    | writing, gifts or other      |      |   |
|    |                              |      |   |
| 12 | services                     | Nene |   |
| 13 | Other financial or non-      | None |   |
|    | financial interests          |      |   |
|    |                              |      |   |

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

 Date:
 \_\_\_\_\_20 May 2022

 Your Name:
 \_\_\_\_\_Peter L Anderson

 Manuscript Title:
 Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the

 HPTN 082 study in South Africa and Zimbabwe

 Manuscript number (if known):
 thelancethiv-D-21-00494

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding, | None   |   |
|   | provision of study materials,                             |  |   |
|   | medical writing, article                                  |  |   |
|   | processing charges, etc.)                                 |  |   |
|   | No time limit for this item.                              |  |   |
|   |   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                  | Gilead   | Paid to institution   |
|   | any entity (if not indicated                              |  |   |
|   | in item #1 above).  |  |   |
| 3 | Royalties or licenses                                     | None   |   |
|   |   |  |   |
|   |   |  |   |
| 4 | Consulting fees   | Gilead   | Paid to me  |
|   |   | Merck  | Paid to me  |

|    |  | ViiV | Paid to me |
|----|--|------|------------|
| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |            |
| 6  | Payment for expert testimony   | None |            |
| 7  | Support for attending meetings and/or travel   | None |            |
| 8  | Patents planned, issued or pending   | None |            |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |            |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |            |
| 11 | Stock or stock options   | None |            |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |            |
| 13 | Other financial or non-<br>financial interests   | None |            |

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:12 May 2022 Your Name: Zvavahera Michael Chirenje Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u> Manuscript number (if known): <u>thelancethiv-D-21-00494</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, | None   |   |
|   | provision of study materials,                          |  |   |
|   | medical writing, article                               |  |   |
|   | processing charges, etc.)                              |  |   |
|   | No time limit for this item.                           |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                               | None   |   |
|   | any entity (if not indicated                           |  |   |
|   | in item #1 above).                                     |  |   |
| 3 | Royalties or licenses                                  | None   |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | None   |   |
|   |  |  |   |
|   |  |  |   |
| 5 | Payment or honoraria for                               | None   |   |
|   | lectures, presentations,                               |  |   |
|   | speakers bureaus,                                      |  |   |

|    | manuscript writing or        |      |  |
|----|------------------------------|------|--|
|    | educational events           |      |  |
| 6  | Payment for expert           | None |  |
|    | testimony                    |      |  |
|    |                              |      |  |
| 7  | Support for attending        | None |  |
| '  | meetings and/or travel       |      |  |
|    | meetings and/or traver       |      |  |
|    |                              |      |  |
|    |                              |      |  |
|    |                              |      |  |
| 8  | Patents planned, issued or   | None |  |
|    | pending                      |      |  |
|    |                              |      |  |
| 9  | Participation on a Data      | None |  |
| 9  | Safety Monitoring Board or   |      |  |
|    |                              |      |  |
|    | Advisory Board               |      |  |
| 10 | Leadership or fiduciary role | None |  |
|    | in other board, society,     |      |  |
|    | committee or advocacy        |      |  |
|    | group, paid or unpaid        |      |  |
| 11 | Stock or stock options       | None |  |
|    |                              |      |  |
|    |                              |      |  |
| 12 | Receipt of equipment,        | None |  |
|    | materials, drugs, medical    |      |  |
|    | writing, gifts or other      |      |  |
|    | services                     |      |  |
| 13 | Other financial or non-      | None |  |
| 12 |                              |      |  |
|    | financial interests          |      |  |
|    |                              |      |  |

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.



 Date:
 \_\_\_\_\_\_\_11 MAY 2022 \_\_\_\_\_\_\_

 Your Name:
 \_\_\_\_\_\_\_Nyaradzo M Mgodi \_\_\_\_\_\_\_

 Manuscript Title:
 Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the HPTN 082 study in South Africa and Zimbabwe

 Manuscript number (if known):
 thelancethiv-D-21-00494

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or pending   | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>27 May 2022</u> Your Name: <u>LINDA-GAIL BEKKER</u> Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u> Manuscript number (if known): <u>thelancethiv-D-21-00494</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | <u>X</u> None  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone  |   |
| 3 | Royalties or licenses  | XNone  |   |
| 4 | Consulting fees  | X None   |   |

| 5  | Payment or honoraria for lectures, presentations, | <u>×</u> None |  |
|----|---|---------------|--|
|    |   |               |  |
|    | speakers bureaus,                                 |               |  |
|    | manuscript writing or                             |               |  |
| 6  | educational events                                | X None        |  |
| 6  | Payment for expert                                | XNone         |  |
|    | testimony   |               |  |
| 7  | Support for attending                             | X None        |  |
| /  | meetings and/or travel                            | <u> </u>      |  |
|    |   |               |  |
|    |   |               |  |
| 8  | Patents planned, issued or                        | <u>×</u> None |  |
|    | pending   |               |  |
|    |   |               |  |
| 9  | •   | <u>×</u> None |  |
|    | Safety Monitoring Board or                        |               |  |
|    | Advisory Board                                    |               |  |
| 10 | , ,   | XNone         |  |
|    | in other board, society,                          |               |  |
|    | committee or advocacy                             |               |  |
| 11 | group, paid or unpaid                             | X None        |  |
| 11 | Stock or stock options                            |               |  |
|    |   |               |  |
| 12 | Receipt of equipment,                             | X None        |  |
|    | materials, drugs, medical                         |               |  |
|    | writing, gifts or other                           |               |  |
|    | services  |               |  |
| 13 | Other financial or non-                           | XNone         |  |
|    | financial interests                               |               |  |
|    |   |               |  |

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date:                         | 5/11/2022  |
|-------------------------------|--|
| Your Name:                    | Mark Marzinke  |
| Manuscript Title:             | Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the HPTN 082 study in South Africa and Zimbabwe |
| Manuscript Number (if known): | thelancethiv-D-21-00494  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | g of the work   |
| 1 | All support for the present   |  |   |
|   | manuscript (e.g.,   | NIH  | Grant; payments made to my institution  |
|   | funding, provision<br>of study materials,<br>medical writing,           |  | Click the tab key to add additional rows.   |
|   | article processing<br>charges, etc.)<br>No time limit for<br>this item. |  |   |
|   |   | Time frame: past 36 mont   | hs  |
| 2 | Grants or<br>contracts from   | None   |   |
|   | any entity (if not  | ViiV Healthcare  | Grant; payments made to my institution  |
|   | indicated in item   | Gilead   | Grant; payments made to my institution  |
|   | #1 above).  | Merck  | Industry Contract; payments made to my institution                                  |

|  |                                   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)            |
|--|-----------------------------------|--|--|
| 3  | Royalties or<br>licenses          | None   | Develtion consciented with Contemporary  |
|  |                                   | Elsevier   | Royalties associated with Contemporary<br>Practices for Clinical Chemistry, 4 <sup>th</sup> Ed |
|  |                                   |  |  |
| 4  | Consulting fees                   | ⊠ None   |  |
|  |                                   |  |  |
|  |                                   |  |  |
| 5  | Payment or<br>honoraria for       |  |  |
|  | lectures,<br>presentations,       | American Association for Clinical Chemistry  | Honoraria for lectures   |
|  | speakers<br>bureaus,              |  |  |
|  | manuscript<br>writing or          |  |  |
|  | educational<br>events             |  |  |
| 6  | Payment for expert testimony      | ⊠ None   |  |
|  |                                   |  |  |
|  |                                   |  |  |
| 7  | Support for attending             |  |  |
|  | meetings and/or<br>travel         | American Association for Clinical Chemistry  | Travel support to meeting  |
|  |                                   | Mass Spectrometry Applications to the Clinical<br>Laboratory                                 | Travel support to meeting  |
|  |                                   | University of Utah   | Travel support for lecture   |
| 8  | Patents planned, issued or        | ⊠ None   |  |
|  | pending                           |  |  |
|  |                                   |  |  |
| 9  | Participation on<br>a Data Safety | ⊠ None   |  |
|  | Monitoring<br>Board or            |  |  |
|  | Advisory Board                    |  |  |
| 10   Leadership or   Image: None     fiduciary role in   Image: None |                                   |  |  |
|  | other board,                      | American Association for Clinical Chemistry  | Board of Directors   |

|      |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if payments wererelationship or indicate none (add rows as needed)made to you or to your institution) |  |  |
|------|---|---|--|--|
|      | society,<br>committee or<br>advocacy group,<br>paid or unpaid                                   | Commission on Accreditation in Clinical ChemistryCommissionerAmerican Board for Clinical ChemistryBoard of Directors  |  |  |
| 11   | Stock or stock<br>options   | None  |  |  |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | None  |  |  |
| 13   | Other financial or<br>non-financial<br>interests  | None  |  |  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                 |   |  |  |

Date: 17 MAY 2022 Your Name: Sinead Delany-Moretlwe Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u> Manuscript number (if known): <u>thelancethiv-D-21-00494</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or pending   | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_\_\_\_\_May 19,2022\_\_\_

Your Name: \_\_\_\_\_Connie Celum\_\_\_

Manuscript Title: <u>Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in the</u> <u>HPTN 082 study in South Africa and Zimbabwe</u>

Manuscript number (if known): thelancethiv-D-21-00494

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   | Funding for research to my institution  |
|   | manuscript (e.g., funding,    | NIH  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   | Grants to my institution  |
|   | any entity (if not indicated  | NIH  |   |
|   | in item #1 above).            | BMGF   |   |
|   |                               | USAID  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   | Payments to me  |
|   |                               | Merck scientific advisor   |   |

|    |   | Gilead scientific advisor |  |
|----|---|---------------------------|--|
| 5  | Payment or honoraria for                        | XNone                     |  |
|    | lectures, presentations,                        |                           |  |
|    | speakers bureaus,                               |                           |  |
|    | manuscript writing or                           |                           |  |
|    | educational events                              |                           |  |
| 6  | Payment for expert                              | None                      | Payment to me  |
|    | testimony                                       | Gilead                    |  |
|    |   |                           |  |
| 7  | Support for attending<br>meetings and/or travel | None                      | Payment to me  |
|    |   | Gilead                    |  |
|    |   |                           |  |
| 8  | Patents planned, issued or                      | XNone                     |  |
|    | pending   |                           |  |
|    |   |                           |  |
| 9  | Participation on a Data                         | None                      | Participation in DSMB and advisory boards; no payments |
|    | Safety Monitoring Board or                      | HPTN                      |  |
|    | Advisory Board                                  | LSHTM                     |  |
| 10 | Leadership or fiduciary role                    | XNone                     |  |
|    | in other board, society,                        |                           |  |
|    | committee or advocacy                           |                           |  |
|    | group, paid or unpaid                           |                           |  |
| 11 | Stock or stock options                          | XNone                     |  |
|    |   |                           |  |
| 12 | Receipt of equipment,                           | None                      | Donated for research studies                           |
| 12 | materials, drugs, medical                       | Gilead study drugs        |  |
|    | writing, gifts or other                         |                           |  |
|    | services  |                           |  |
| 13 | Other financial or non-                         | X None                    |  |
|    | financial interests                             |                           |  |
|    |   |                           |  |

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.